A Multicenter, Parallel-Group, Controlled, Randomized, Double-Blind Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma.
Phase of Trial: Phase III
Latest Information Update: 01 May 2017
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Celgene Corporation
- 08 Dec 2015 Results of matched comparison between RevLite and other two phase III trials ( MM009 and MM010) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 08 Jun 2009 A subset analyses of pooled data from this trial and study MM010 has been published in the European Journal of Hematology, according to a Celgene media release.
- 08 Jun 2009 Subset analyses of updated, pooled data from this trial and study MM010 are to be presented at the 14th Congress of the European Hematology Association (EHA), according to a Celgene media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History